Assessment of human papilloma viral load of archival cervical intraepithelial neoplasia by real-time polymerase chain reaction in a Turkish population

The purpose of this study was to determine the existence, and viral load of human papilloma virus (HPV) subtypes 16 and 18 in paraffinized cervical intraepithelial neoplasia (CIN) samples by real-time polymerase chain reaction (RT-PCR). Overall 94 women were included. Of these patients 47 (50%) had CIN I, 27 (28.8%) had CIN II, and 20 (21.2%) had CIN III. HPV positivity for these three groups were 4.2%, 14.8% and 45%, respectively. HPV positivity in CIN III patients was significantly higher than CIN I (OR = 18.41, 95% CI 3.00-145.73; p < 0.001), and CIN II patients (OR = 4.70, 95% CI 1.00-23.76; p = 0.05). The difference between CIN I and II was not significant (p = 0.18). Viral loads were 10(2), and 10(4) copy/ml for two CIN I patients; 10(2), 10(3), and 10(5) for three CIN II patients; and 10(2), 10(3), 10(4), 10(4), 10(5), 10(5), and 10(6) copy/ml for eight patients with CIN III. Viral load of the remaining one patient could not be assessed. No significant variance was noted among the groups with respect to viral load (p = 0.73). RT-PCR had important advantages of detecting, typing, and quantifying at the same time. Although HPV positivity was increased significantly by the degree of lesions, this relation was not observed for viral load.

Human papilloma virus; Real-time polymerase chain reaction; Viral load; Cervical intraepithelial neoplasia

[1] Parkin D.M., Pisani P., Ferlay J.: "Global cancer statistics". CA Cancer J. Clin., 1999, 49, 33.

[2] Nanda K., McCrory D.C., Myers E.R. et al.: "Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review". Ann. Intern. Med., 2000, 132, 810.

[3] zur Hausen H.: "Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers". Cancer Res., 1989, 49, 4677.

[4] Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J. et al.: "Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group". J. Natl Cancer Inst., 1995, 87, 796.

[5] Woodworth C.D., Doniger J., DiPaolo J.A.: "Immortalization of human keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma". J. Viral., 1989, 63, 159.

[6] Wang-Johanning F., Lu D.W., Wang Y., Johnson M.R., Johanmng G.L: "Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis". Cancer, 2002, 94, 2199.

[7] Cuzick J., Terry G., Ho L., Hollingworth T., Anderson M “Human paplllomawrus type 16 m cemcal smears as predICtor of high-grade cervical intraepithelial neoplasia". Lancet, 1992, 339, 959.

[8] Schneider A., Zahm D.M., Greinke C., Kirchmayr R., Nindl I "Different detectability of high-risk HPV in smears from incident and prevalent high-grade squamous intraepithelial lesions of the cervix". Gynecol. Oneal., 1997, 65, 399.

[9] Dalstein V, Riethmuller D., Pretet J.L, Le Bail Carval K., Sautiere J.L., Carbillet J.P. et al.: "Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study". Int. J Cancer, 2003, 106, 396.

[10] Healey S.M., Aronson K.J., Mao Y., Schlecht N.F., Mery L.S., Ferenczy A., F ranco E.L.: "Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada". Sex. Transm. Dis.. 2001, 28, 694.

[11] Sun C.A., Liu J.F., Wu D.M., Nieh S., Yu C.P., Chu T.Y: "Viralload of high-risk human papillomavirns in cervical squamous intraepithelial lesions". Int. J. Gynaecol. Obstet., 2002, 76, 41.

[12] Hernandez-Hernandez D.M., Ornelas-Bernal L., Guido-Jimenez M., Apresa-Garcia T., Alvarado-Cabrero I., Salcedo-Vargas M. et al.: "Association between high-risk human papillomavirns DNA load and precursor lesions of cervical cancer in Mexican women". Gynecol. Oncol., 2003, 90, 310.

[13] Biedermann K., Dandachi N., Trattner M., Yogi G., Doppelmayr H., More E. et al.: " Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirns in archival cervical cancer tissue". J. Clin. Microbial., 2004, 42, 3758.

[14] zur Hausen H.: " Immortalization of human cells and their mahgnant conversion by high risk human papillomavirns genotypes" Semin. Cancer Biol.. 1999, 9, 405.

[15] Schiffman M.H., Bauer H.M., Hoover R.N., Glass A.G., Cadell D.M., Rush B.B. et al.: " Epidemiologic evidence showing that human papillomavirns infection causes most cervical intraepithelial neoplasia". J. Natl. Cancer Inst., 1993, 85, 958.

[16] Keerti Y.S., Howley P.M.: "Papillomavirnses". In: Fields B.N., Knipe D.M., Howley P.M. et al. (eds.). Virology. Philadelphia Lippincott-Raven, 1996, 2, 2077.

[17] Josefsson A.M., Magnusson P.K., Gyllensten U.B.: "Human papilloma vims detection by PCR and typing by dot-blot". In: Peeling SP (ed.). Sexually transmitted diseases: methods and protocols. Humana Pres, Inc., Totowa, NJ. 1999, 171.

[18] Jacobs M.Y., Walboomers J.M., van Beek J., Yoorhorst F.J., Verheijen R.H., Meijcr C.J. et al.: "A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings" Br. J. Cancer, 1999, 81, 114.

[19] Hart K.W., Williams O.M., Thelwell N., Fiander A.N., Brown T., Borysiewicz L.K., Gelder C.M.: " Novel method for detection, typing, and quantification of human papillomavirnses in clinical samples". J. Clin. Microbial.. 2001, 39, 3204.

[20] Zerbini M., Venturoli S., Cricca M., Gallinella G., De Simone P., Costa S. et al.: "Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA". J. Clin. Pathol.. 2001, 54, 377.

[21] Swan D.C., Tucker R.A., Tortolero-Luna G., Mitchell M.F., Wideroff L., Unger E.R. et al.: " Human papillornavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type". J. Clin. Microbial., 1999, 37, 1030.

[22] Sun C.A., Lai H.C., Chang C.C., Neih S., Yu C.P., Chu T.Y.:'The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix". Gynecol. Oncol., 2001, 83, 95.

[23] Abba M.C., Mouron S.A., Gomez M.A., Dulout F.N., GohJow C.D.: "Association of human papillomavirus viral load with HPV 16 and high-grade intraepithelial lesion". Int. J. Gynecol Cancer, 2003, 13, 154.

[24] Y litalo N., Sorensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Ponten J. et al.: "Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study". lancet, 2000, 355, 2194.

[25] van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A. et al.: "Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance". Int. J. Cancer, 2002, 98, 590.

[26] Moberg M., Gustavsson I., Gyllensten U.: "Real-time PCR-based system for simultaneous quantification of human papillornavirus types associated with high risk of cervical cancer". J. Clin. Microbiol., 2003, 41, 3221.

[27] Gravitt P.E., Burk R.D., Lorincz A., Herrero R., Hildesheim A., Sherman M.E. et al.: "A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation". Cancer Epidemiol. Biomarkers Prev., 2003, 12, 477.

[28] Lorincz A.T., Castle P.E., Sherman M.E., Scott D.R., Glass A.G., Wacholder S. et al.: "Viral load of human papillornavirus and risk of CIN3 or cervical cancer". Lancet, 2002, 360, 228.